

EARLY CLINICAL TRIALS EXPERTISE

ORAL PRESENTATIONS

ASH 2015

- Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients.
 - Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study.

TAT 2015

- Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438.

PUBLICATIONS

- Zinzani PL, **Ribrag V**, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. *Blood*. 2017 Jul 20;130(3):267-270.
- Ribrag V**, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJS, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. *Haematologica*. 2017 May;102(5):903-909.
- Ribrag V**, Koscielny S, Bosq J, Leguay T, Casanovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Guill S, Ojeda-Urbe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. 2016 Nov 1;34(31):3733-3739.
- Armand P, Shipp MA, **Ribrag V**, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. *J Clin Oncol*. 2016 Jun 27. pii: JCO673467 [Epub ahead of print]
- Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, **Ribrag V**, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas. *Clin Cancer Res*. 2016;22(23):5696-5705.

Vincent Ribrag

MD



General background

Vincent Ribrag attended the University of Science and Medical School of South-Paris University between 1978 and 1985. In 1990-1991 he obtained his Master of Science in Molecular Biology, with Professor JC Kaplan. In the years 1990-1992 he also received his Diplôme d'Études Approfondies in molecular and cellular pharmacology at the Pierre et Marie Curie (Paris VI) University with Professor Ascher. He obtained his board certification in Hematology and discussed a thesis (silver medal) at the Paris XI Faculty of Medicine entitled "VIP (etoposide, ifosfamide, cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease."

Dr Ribrag is a tenure-track specialist at Gustave-Roussy Institute and has been nominated head of the Hematology multidisciplinary committee in Gustave-Roussy. Among numerous experimental activities, he counts a Laboratoire in clinical pharmacology (URA 147 CNRS, U-140 INSERM) with Dr A Gouyette; works in enzymology, the ICGM: INSERM U-363 at the Hôpital Cochin in Paris; the Unité INSERM U U1170: Animal MCL models and drug discovery and is head of the translational research lab in hematology. Dr Ribrag is member of several international cancer societies, namely the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), the Société Française de Greffe de Moelle (SFGM), the Société Française d'Hématologie (SFH), the Groupe Français des Myélodysplasies (GFM) where he serves as scientific secretary since 1998. He is also part of the Lysa Scientific and Administrative Committees and of the European Scientific Committee of the Mantle Cell Lymphoma study group since 2001 and associated Head of early trials with Martin Dreyling.